2024-12-16 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Comparison & Divergence:**

Merck & Co Inc (MRK) is a pharmaceutical company developing and manufacturing prescription medicines and vaccines.  The cumulative return of MRK (67.60%) significantly underperformed the S&P 500 (VOO) (120.91%) over the analyzed period. The difference is -53.3%, placing it at the 9.3rd percentile of its historical divergence from the S&P 500 based on provided data.  This indicates MRK's underperformance relative to the broader market.  The provided alpha consistently shows negative values, suggesting underperformance relative to the market benchmark after adjusting for risk.


**2. Recent Price Movement:**

* **Closing Price:** $102.00
* **5-Day Moving Average:** $101.56
* **20-Day Moving Average:** $100.58
* **60-Day Moving Average:** $105.14

The price is currently below its 5 and 20-day moving averages, but above its 60-day moving average, suggesting a potential short-term downward trend, but a longer-term upward trend is possible.

**3. Technical Indicators & Expected Return:**

* **RSI:** 57.92  (Neither overbought nor oversold, suggesting a neutral sentiment).
* **PPO:** 0.29  (Positive value indicating bullish momentum).
* **20-Day Relative Divergence Change:** -0.4  (Indicates a recent slight downward trend).
* **Expected Return (vs S&P 500):** 0.0% (This suggests that long-term (2+ years) investment may not yield a significant outperformance compared to the S&P 500 based on the provided data. This is a forecast based on historical data,  and doesn't guarantee future performance.)

The current price of $102.00 doesn't indicate a significant recent sharp increase or decrease. The provided information doesn't contain enough information to analyze or determine if this price is considered high or low.

**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in both EPS and revenue.  There is no consistent upward or downward trend clearly evident in just this snapshot.

* **Revenue:** Revenue shows relatively stable levels around $16B, with minor fluctuations between quarters. There isn't a clear strong upward trend.
* **EPS:** EPS fluctuates significantly across quarters, making it difficult to establish a clear trend without additional context and information.

**Analysis of Financials (Provided Tables):**

**Revenue and Profitability:**  Revenue has remained relatively stable with slight quarter-to-quarter variation.  Profit margins are generally high but exhibit minor fluctuation, suggesting relative stability in profitability.

**Capital and Profitability:** Equity shows a general upward trend but exhibits some quarter-to-quarter volatility. ROE is inconsistent, indicating varying levels of return on equity throughout the provided period.  The negative ROE in 2023 Q4 is noteworthy and warrants further investigation (although outside of the scope of this analysis which is based on provided data only).

**5.  News and Recent Issues:**

No news or market outlook information was provided.  Analyst opinions and performance highlights are also missing.  Analysis would require this data.

**6.  Overall Analysis:**

Merck & Co Inc (MRK) shows a recent period of underperformance compared to the S&P 500.  Technical indicators suggest a neutral to slightly bullish short-term sentiment.  Earnings data reveals some volatility in both revenue and EPS without a clearly defined trend.  While the company shows relatively high profit margins and stable revenue, ROE demonstrates inconsistency.  More information is needed on recent news, market outlook, and analyst opinions to provide a more comprehensive analysis.  The limited data provided suggests the potential for a long-term investment that might not significantly outperform the S&P 500.  Further investigation, beyond the scope of this report, is necessary before making investment decisions.  This report is solely based on the provided data and does not constitute financial advice.
